Barbara Klencke
2020
In 2020, Barbara Klencke earned a total compensation of $2.8M as Chief Development Officer at ProNAi Therapeutics, a 186% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $200,294 |
|---|---|
| Option Awards | $2,076,520 |
| Salary | $500,735 |
| Other | $5,218 |
| Total | $2,782,767 |
Klencke received $2.1M in option awards, accounting for 75% of the total pay in 2020.
Klencke also received $200.3K in non-equity incentive plan, $500.7K in salary and $5.2K in other compensation.
Rankings
In 2020, Barbara Klencke's compensation ranked 4,152nd out of 13,090 executives tracked by ExecPay. In other words, Klencke earned more than 68.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,152 out of 13,090 | 68th |
Division Manufacturing | 1,672 out of 5,624 | 70th |
Major group Chemicals And Allied Products | 640 out of 2,257 | 72nd |
Industry group Drugs | 548 out of 1,957 | 72nd |
Industry Pharmaceutical Preparations | 417 out of 1,462 | 72nd |
Source: SEC filing on April 23, 2021.
Klencke's colleagues
We found three more compensation records of executives who worked with Barbara Klencke at ProNAi Therapeutics in 2020.